{{medref|date=February 2010}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477164594
| IUPAC_name = 1-[(4-Methoxybenzoyl)]-2-pyrrolidinone
| image = Aniracetam.svg
| width = 200
| image2 = Aniracetam3d.png
| width2 = 175

<!--Clinical data-->
| tradename =  Ampamet, Memodrin, Pergamid
| Drugs.com = {{drugs.com|international|aniracetam}}
| pregnancy_category =
| legal_US_comment = Not approved
| legal_status = Unscheduled
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism =
| elimination_half-life = 1–2.5 hours
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 4133
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 72432-10-1
| ATC_prefix = N06
| ATC_suffix = BX11
| PubChem = 2196
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04599
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2111
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5L16LKN964
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01883
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 47943
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 36994

<!--Chemical data-->
| C=12 | H=13 | N=1 | O=3
| molecular_weight = 219.237 g/mol
| smiles = O=C2N(C(=O)c1ccc(OC)cc1)CCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZXNRTKGTQJPIJK-UHFFFAOYSA-N
}}

'''Aniracetam''' (brand names '''Draganon''', '''Sarpul''', '''Ampamet''', '''Memodrin''', '''Referan'''), also known as '''''N''-anisoyl-2-pyrrolidinone''', is a [[racetam]] which is sold in [[Europe]] as a [[prescription drug]]. It is not approved by the [[Food and Drug Administration]] for use in the [[United States]].<ref>{{cite journal |author=Malykh AG |author2=Sadaie MR |title=Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. |journal=Drugs. |volume=70 |issue=3 |pages=287–312 |date=Feb 2010 |pmid=20166767 |doi=10.2165/11319230-000000000-00000}}</ref>

== Pharmacology ==
Aniracetam has also been shown to positively modulate the [[AMPA receptor]].<ref>{{cite journal | author = Ito | journal = J. Physiol. | year = 1990 | volume = 424 | pages = 533–543 | pmid = 1975272 | last2 = Tanabe | first2 = S | last3 = Kohda | first3 = A | last4 = Sugiyama | first4 = H | title = Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam | pmc = 1189827|display-authors=etal}}</ref> 

When ingested orally aniracetam is quickly broken down via first pass hepatic metabolism.  The primary metabolites of aniracetam are [[N-anisoyl-GABA|''N''-anisoyl-GABA]], (70–80%), [[2-Pyrrolidinone]] and [[p-Anisic acid|''p''-anisic acid]] (20–30%).<ref>{{cite journal | pmid = 8199398 | year = 1994 | last1 = Lee | first1 = CR | last2 = Benfield | first2 = P | title = Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders | volume = 4 | issue = 3 | pages = 257–73 | journal = Drugs & aging | doi=10.2165/00002512-199404030-00007}}</ref><ref>{{cite book|title=Schizophrenia: New Insights for the Healthcare Professional: 2013 Edition|url=https://books.google.com/books?id=zsSvvZfC8cgC&pg=PA152|date=22 July 2013|publisher=ScholarlyEditions|isbn=978-1-4816-6196-6|pages=152–}}</ref><ref name="TestaMayer2003">{{cite book|author1=Bernard Testa|author2=Joachim M. Mayer|title=Hydrolysis in Drug and Prodrug Metabolism|url=https://books.google.com/books?id=U-PDqHikphYC&pg=PA109|date=1 August 2003|publisher=John Wiley & Sons|isbn=978-3-906390-25-3|pages=109–}}</ref>

Plasma concentrations are generally in the 5–15 ''μ''g/L range for aniracetam and 5–15&nbsp;mg/L range for ''N''-anisoyl-GABA, a pharmacologically-active metabolite, during the first few hours after oral administration of the drug. These two plasma species may be measured by liquid chromatography-mass spectrometry.<ref>Cai S, Wang L. Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. J. Chromatogr. B 897: 50-54, 2012.</ref><ref>Zhang J, Liang J, Tian Y, et al. Sensitive and selective liquid chromatography-tandem mass spectrometry method for the quantification of aniracetam in human plasma. J. Chromatogr. B 858: 129-134, 2007.</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 10th edition, Biomedical Publications, Seal Beach, CA, 2014, p. 142-143.</ref>

==Synthesis==
The drug was first made in the 1970s by [[Hoffmann-La Roche]].<ref>Patent EP 5 143 Hoffmann-La Roche 1978</ref>{{full|date=June 2013}}<ref>Patent EP 44 088 Hoffmann-La Roche 1978</ref>{{full|date=June 2013}} Synthesis can be accomplished by reacting [[2-pyrrolidone]] with [[anisoyl chloride]] in the presence of [[triethylamine]].<ref name="Kleemann">A. Kleemann, J. Engel, B. Kutscher, D. Reichert: ''Pharmaceutical Substances - Synthesis, Patents, Applications'', 4. Auflage, Thieme 2001, {{ISBN|3-13-115134-X}}.</ref>

[[Image:Aniracetam synthesis 01.svg|480px]]

Alternatively, [[gamma-aminobutyric acid]] can react with anisoyl chloride. Ring closure can be accomplished in the presence of [[thionyl chloride]].<ref name="Kleemann"/>

[[Image:Aniracetam synthesis 02.svg|710px]]

==See also==
* [[AMPA receptor positive allosteric modulator]]

==References==
{{Reflist|2}}

{{Nootropics}}
{{Ionotropic glutamate receptor modulators}}
{{Racetams}}

[[Category:AMPA receptor positive allosteric modulators]]
[[Category:Nootropics]]
[[Category:Pyrrolidines]]
[[Category:Racetams]]